Nevertheless, the combined use of danazol, erythropoiesis-stimulating agents, iron chelation therapy and ruxolitinib dose optimization have been proposed as a means of mitigating the burden of anemia and may be useful in CALR-mutated patients [33–37]. The gene discussed is CALR; the disease is anemia.